Alx oncology reports positive interim phase 2 aspen-06 clinical trial results of evorpacept for the treatment of advanced her2-positive gastric cancer

-- evorpacept is the first cd47 blocker to show activity in a global randomized study in solid tumors

ALXO Ratings Summary

ALXO Quant Ranking